StockData
Corbus Pharmaceuticals Holdings, Inc. logo

Corbus Pharmaceuticals Holdings, Inc. (CRBP) stock

CRBPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 6/30
$2.75−0.26 (-8.80%)

Close on Nov 18, 2026Market cap $53.09MP/E –Yield –

Corbus Pharmaceuticals operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Corbus Pharmaceuticals's operating income for the twelve months ending Jun 30, 2026 was -$106.88M. For fiscal 2025 it was -$85.31M. The highest annual figure on record is -$557.28K in fiscal 2013.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$85.31M–
FY2024Dec 31, 2024-$48.72M–
FY2023Dec 31, 2023-$45.08M–
FY2022Dec 31, 2022-$39.84M–
FY2021Dec 31, 2021-$55.99M–
FY2020Dec 31, 2020-$122.81M–
FY2019Dec 31, 2019-$77.10M–
FY2018Dec 31, 2018-$56.75M–
FY2017Dec 31, 2017-$32.56M–
FY2016Dec 31, 2016-$19.99M–
FY2015Dec 31, 2015-$8.85M–
FY2014Dec 31, 2014-$2.65M–
FY2013Dec 31, 2013-$557.28K–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$36.19M–
Q1 FY2026Mar 31, 2026-$24.30M–
Q4 FY2025Dec 31, 2025-$21.97M–
Q3 FY2025Sep 30, 2025-$24.42M–
Q2 FY2025Jun 30, 2025-$19.15M–
Q1 FY2025Mar 31, 2025-$19.78M–
Q4 FY2024Dec 31, 2024-$12.61M–
Q3 FY2024Sep 30, 2024-$15.51M–
Q2 FY2024Jun 30, 2024-$10.99M–
Q1 FY2024Mar 31, 2024-$9.62M–
Q4 FY2023Dec 31, 2023-$10.10M–
Q3 FY2023Sep 30, 2023-$9.49M–
Q2 FY2023Jun 30, 2023-$8.19M–
Q1 FY2023Mar 31, 2023-$17.30M–
Q4 FY2022Dec 31, 2022-$10.80M–
Q3 FY2022Sep 30, 2022-$8.18M–
Q2 FY2022Jun 30, 2022-$12.34M–
Q1 FY2022Mar 31, 2022-$8.52M–
Q4 FY2021Dec 31, 2021-$10.00M–
Q3 FY2021Sep 30, 2021-$13.88M–
Q2 FY2021Jun 30, 2021-$16.70M–
Q1 FY2021Mar 31, 2021-$15.41M–
Q4 FY2020Dec 31, 2020-$20.81M–
Q3 FY2020Sep 30, 2020-$33.97M–
Q2 FY2020Jun 30, 2020-$38.14M-2336.6%
Q1 FY2020Mar 31, 2020-$29.89M–
Q4 FY2019Dec 31, 2019-$27.19M–
Q3 FY2019Sep 30, 2019-$25.10M–
Q2 FY2019Jun 30, 2019$1.71M–
Q1 FY2019Mar 31, 2019-$26.52M–
Q4 FY2018Dec 31, 2018-$17.59M–
Q3 FY2018Sep 30, 2018-$14.90M–
Q2 FY2018Jun 30, 2018-$12.39M–
Q1 FY2018Mar 31, 2018-$11.86M–
Q4 FY2017Dec 31, 2017-$10.86M–
Q3 FY2017Sep 30, 2017-$6.96M–
Q2 FY2017Jun 30, 2017-$7.29M–
Q1 FY2017Mar 31, 2017-$7.45M–
Q4 FY2016Dec 31, 2016-$7.57M–
Q3 FY2016Sep 30, 2016-$5.33M–

More Corbus Pharmaceuticals figures

See a number that looks wrong?